Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound's cash sales

Hims & Hers Health Inc : Leerink Partners Raises Target Price to $25 From $17.5

S&P 500 Futures Fall In Premarket Trading; UiPath, Piper Sandler Lag

Hims & Hers (HIMS) Stock Rallies 58% in Five Days — Can the Momentum Last?

Hims & Hers Health Shares up 5.1% Premarket Following Nearly 65% Surge in Past Three Sessions

NASD Most Active Issues

Hims & Hers Plans to Expand Access to FDA-Approved GLP-1 Weight Loss Drugs via Novo Nordisk Collaboration, Limit Compounded Semaglutide and Transition Eligible Patients

Hims & Hers rises 14.5%

Hims & Hers Health Is Maintained at Overweight by Barclays

WW report finds GLP-1 users in its support program lose 61% more weight in one month and 29% more in one year

Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Wednesday; Oracle to Advance, NIO to Decline

Hims & Hers Health : Barclays Raises Target Price to $29 From $25

HIMS-Novo ‘Can’t Quit Each Other’ – Bulls Rally on Wegovy Deal

U.S. RESEARCH ROUNDUP-Howmet Aerospace, Nike, Oracle

Hims & Hers Appoints Eli Lilly Communications Veteran to Lead Branded Weight-Loss Drug Push

Hims & Hers appoints Kathryn Beiser as chief communications officer

Hims & Hers Names Kathryn Beiser as Chief Communications Officer

Wall Street Gets Less Bearish on Hims & Hers After Novo Nordisk Truce. Stock Gains Could Still Be Limited. -- Barrons.com

Hims & Hers' Deal With Novo Nordisk Removes Litigation, Credit Risks, BofA Says